Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

NCT ID: NCT03723798

Last Updated: 2022-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 172 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-08
• Study Completion Date: 2018-10-08

Brief Summary

This is a phase 2, multicenter, double-blind, placebo control, randomized study to evaluate the efficacy and safety of orally administered SA001 compared to placebo in patients with Dry Eye Syndrome.

The clinical trial consists of a wash-out period of 14 days, a treatment period of 12 weeks, and a follow-up period of 1 week after administration of the Investigational Product. If the subject voluntarily signs the informed consent form(ICF), the investigator conducts screening tests and check medical history to evaluate the subject's suitability. As a result of the screening test, eligible subjects should stop using the prior medication for dry eye syndrome during the 14 days of observation period, and if necessary, subjects can use rescue drug(artificial tears) for the first 11 days, and then discontinue all eye drops including rescue drug(artificial tears) for 3 days. And all of these subjects will be randomized in a 1:1:1:1 ratio to receive 3 different doses of investigational product (SA001 or placebo) everyday for 12 weeks. During the treatment period, If necessary, subjects can use the rescue drug (artificial tears), and the number of administration of rescue drug is limited to 3 times a day, and when used, the administration time should be recorded in the subject's diary.

Subjects should visit to the study site on 2, 4, 8 and 12 weeks after starting dosing investigational product. Efficacy evaluation results are collected from both eyes, and the primary evaluation variable is analyzed using the test results collected from 'Worse eye' (the eye with the worse keratoconjunctival staining result among both eyes). Worse eye will be determined at the baseline visit and, if the results of both eyes are the same, the test result of the left eye is used.

Conditions

Dry Eye Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Group 1

SA001 Low dose

Group Type: EXPERIMENTAL

SA001 Low dose

Intervention Type: DRUG

3 tablets b.i.d for 12 weeks

Group 2

SA001 Mid dose

Group Type: EXPERIMENTAL

SA001 Mid dose

Intervention Type: DRUG

3 tablets b.i.d for 12 weeks

Group 3

SA001 High dose

Group Type: EXPERIMENTAL

SA001 High dose

Intervention Type: DRUG

3 tablets b.i.d for 12 weeks

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

3 tablets b.i.d for 12 weeks

Interventions

SA001 Low dose

3 tablets b.i.d for 12 weeks

Intervention Type: DRUG

SA001 Mid dose

3 tablets b.i.d for 12 weeks

Intervention Type: DRUG

SA001 High dose

3 tablets b.i.d for 12 weeks

Intervention Type: DRUG

Placebo

3 tablets b.i.d for 12 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age over 19

2. Patient who meets all of the following criteria in at least one of both eyes

• Fluorescein corneal staining score ≥ 2
• Schirmer test ≤ 10mm in 5 mins
• Tear break-up time ≤ 10 secs

3. Patient who diagnosed with dry eye syndrome at the time of screening and who have dry eye symptoms (dryness, discomfort, foreign body sensation, pain, vision fluctuation, etc.)

4. Patient who agrees not to use eye drops other than the rescue drugs provided during the clinical trial period

5. Patient who can understand the clinical trial and voluntarily signs an informed consent

Exclusion Criteria

1. Clinically significant ophthalmic diseases not caused by dry eye disease (corneal surface disease, abnormal corneal sensitivity, abnormal tear excess, etc.) that may confuse the interpretation of clinical trial results

2. In case of being treated with anti-inflammatory therapy for dry eye, such as steroid or non-steroidal anti-inflammatory eye drops, autologous serum eye drops, etc.

3. In case of administration of steroids or immunosuppressants (azathioprine, tacrolimus, cyclosporine, mofetil mycophenolate, etc.)

4. Patient who has worn contact lenses within 72 hours prior to screening or need to wear contact lenses during the clinical trial period

5. A history of intraocular surgery within 90 days prior to screening

6. Active eye infection symptoms such as anterior uveitis, anterior blepharitis, and Steven-Johnson syndrome

7. Patient with an eye allergy or who are currently receiving treatment for an allergic eye disease (using antihistamines, etc.)

8. Autoimmune disease (ex. Sjögren's syndrome, Rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, etc.)

9. Patient who needs surgery due to surface elevation caused by Meibomian Gland Dysfunction (MGD)

10. A history of corneal transplantation or neurotrophic keratitis

11. Patient who has an intraocular pressure of 25 mmHg or higher in one or more of both eyes or have been diagnosed with glaucoma

12. Patient who has undergone vision correction surgery such as LASIK (Laser-Assisted in Situ Keratomileusis) within 12 months prior to screening

13. Patient who has undergone silicone lacrimal punctal occlusion or cauterization of the punctum within 90 days prior to screening. However, patient who has undergone collagen lacrimal punctal occlusion can be enrolled.

14. Hypersensitivity to the ingredients of the investigational product including rebamipide

15. Clinically significant liver, kidney, nervous system, immune system, respiratory or endocrine disease, blood/tumor disease, cardiovascular disease, mental disease (mood disorder, obsessive-compulsive disorder, etc.) or a history of those diseases

16. Patient who shows the following examination findings at visit 1 (screening visit)

• WBC ≤ 4,000/mm3
• Platelets ≤ 100,000/mm3
• AST/ALT/ALP ≥ 3 times the upper limit of normal(ULN)
• Total bilirubin ≥ 1.5 times the upper limit of normal(ULN)

17. A woman who has a positive Serum hCG test at the screening visit (Visit 1), or who does not agree to use at least one effective contraceptive method that is medically acceptable

18. Take oral contraceptives during the study period

19. Pregnant or lactating women

20. A history of drug or alcohol abuse

21. Participation in an investigational drug or device trial within 30 days prior to screening

22. Any condition that, in the opinion of the investigator, would inappropriate to participate in the clinical trial

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Choun-Ki Joo, M.D.,Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Seoul St. Mary's Hospital

Locations

Seoul St. Mary's Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

SJSA001_03

Identifier Type: -

Identifier Source: org_study_id